Cargando…

A Robust Prognostic Gene Signature Based on eRNAs-Driven Genes in Prostate Cancer

Prostate cancer (PCa) is the second most common malignancy in men, but its exact pathogenetic mechanisms remain unclear. This study explores the effect of enhancer RNAs (eRNAs) in PCa. Firstly, we screened eRNAs and eRNA -driven genes from The Cancer Genome Atlas (TCGA) database, which are related t...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Shuaishuai, Wang, Zheng, Zhao, Li, Zhao, ChenHui, Yuan, DaJiang, Wang, Jingqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276043/
https://www.ncbi.nlm.nih.gov/pubmed/34267780
http://dx.doi.org/10.3389/fgene.2021.676845
_version_ 1783721835884445696
author Fan, Shuaishuai
Wang, Zheng
Zhao, Li
Zhao, ChenHui
Yuan, DaJiang
Wang, Jingqi
author_facet Fan, Shuaishuai
Wang, Zheng
Zhao, Li
Zhao, ChenHui
Yuan, DaJiang
Wang, Jingqi
author_sort Fan, Shuaishuai
collection PubMed
description Prostate cancer (PCa) is the second most common malignancy in men, but its exact pathogenetic mechanisms remain unclear. This study explores the effect of enhancer RNAs (eRNAs) in PCa. Firstly, we screened eRNAs and eRNA -driven genes from The Cancer Genome Atlas (TCGA) database, which are related to the disease-free survival (DFS) of PCa patients;. screening methods included bootstrapping, Kaplan–Meier (KM) survival analysis, and Pearson correlation analysis. Then, a risk score model was established using multivariate Cox analysis, and the results were validated in three independent cohorts. Finally, we explored the function of eRNA-driven genes through enrichment analysis and analyzed drug sensitivity on datasets from the Genomics of Drug Sensitivity in Cancer database. We constructed and validated a robust prognostic gene signature involving three eRNA-driven genes namely MAPK15, ZNF467, and MC1R. Moreover, we evaluated the function of eRNA-driven genes associated with tumor microenvironment (TME) and tumor mutational burden (TMB), and identified remarkable differences in drug sensitivity between high- and low-risk groups. This study identified a prognostic gene signature, which provides new insights into the role of eRNAs and eRNA-driven genes while assisting clinicians to determine the prognosis and appropriate treatment options for patients with PCa.
format Online
Article
Text
id pubmed-8276043
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82760432021-07-14 A Robust Prognostic Gene Signature Based on eRNAs-Driven Genes in Prostate Cancer Fan, Shuaishuai Wang, Zheng Zhao, Li Zhao, ChenHui Yuan, DaJiang Wang, Jingqi Front Genet Genetics Prostate cancer (PCa) is the second most common malignancy in men, but its exact pathogenetic mechanisms remain unclear. This study explores the effect of enhancer RNAs (eRNAs) in PCa. Firstly, we screened eRNAs and eRNA -driven genes from The Cancer Genome Atlas (TCGA) database, which are related to the disease-free survival (DFS) of PCa patients;. screening methods included bootstrapping, Kaplan–Meier (KM) survival analysis, and Pearson correlation analysis. Then, a risk score model was established using multivariate Cox analysis, and the results were validated in three independent cohorts. Finally, we explored the function of eRNA-driven genes through enrichment analysis and analyzed drug sensitivity on datasets from the Genomics of Drug Sensitivity in Cancer database. We constructed and validated a robust prognostic gene signature involving three eRNA-driven genes namely MAPK15, ZNF467, and MC1R. Moreover, we evaluated the function of eRNA-driven genes associated with tumor microenvironment (TME) and tumor mutational burden (TMB), and identified remarkable differences in drug sensitivity between high- and low-risk groups. This study identified a prognostic gene signature, which provides new insights into the role of eRNAs and eRNA-driven genes while assisting clinicians to determine the prognosis and appropriate treatment options for patients with PCa. Frontiers Media S.A. 2021-06-29 /pmc/articles/PMC8276043/ /pubmed/34267780 http://dx.doi.org/10.3389/fgene.2021.676845 Text en Copyright © 2021 Fan, Wang, Zhao, Zhao, Yuan and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Fan, Shuaishuai
Wang, Zheng
Zhao, Li
Zhao, ChenHui
Yuan, DaJiang
Wang, Jingqi
A Robust Prognostic Gene Signature Based on eRNAs-Driven Genes in Prostate Cancer
title A Robust Prognostic Gene Signature Based on eRNAs-Driven Genes in Prostate Cancer
title_full A Robust Prognostic Gene Signature Based on eRNAs-Driven Genes in Prostate Cancer
title_fullStr A Robust Prognostic Gene Signature Based on eRNAs-Driven Genes in Prostate Cancer
title_full_unstemmed A Robust Prognostic Gene Signature Based on eRNAs-Driven Genes in Prostate Cancer
title_short A Robust Prognostic Gene Signature Based on eRNAs-Driven Genes in Prostate Cancer
title_sort robust prognostic gene signature based on ernas-driven genes in prostate cancer
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276043/
https://www.ncbi.nlm.nih.gov/pubmed/34267780
http://dx.doi.org/10.3389/fgene.2021.676845
work_keys_str_mv AT fanshuaishuai arobustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer
AT wangzheng arobustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer
AT zhaoli arobustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer
AT zhaochenhui arobustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer
AT yuandajiang arobustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer
AT wangjingqi arobustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer
AT fanshuaishuai robustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer
AT wangzheng robustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer
AT zhaoli robustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer
AT zhaochenhui robustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer
AT yuandajiang robustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer
AT wangjingqi robustprognosticgenesignaturebasedonernasdrivengenesinprostatecancer